Overview
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.
This guidance should be read with NICE's technology appraisal guidance on routine antenatal anti-D prophylaxis for women who are rhesus D negative.
Last reviewed: April 2021
We reviewed the evidence and found nothing new that affects the recommendations in this guidance. See the review decision for more details.
Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.
Diagnostics guidance 25 has been migrated to HealthTech guidance 420.